Company intelligence / Profile preview

ClotProtect Therapeutics Limited

Ownership: Private
Development stage: Preclinical

Overview

ClotProtect is developing CP101, a first-in-class small molecule direct plasmin inhibitor intended for intravenous administration. The drug aims to improve upon the current standard of care (tranexamic acid) by directly inhibiting plasmin—the enzyme responsible for breaking down blood clots—thereby offering greater efficacy in reducing bleeding and deaths after traumatic injury or surgery. The company is advancing chemistry and biology screening with the goal of entering clinical studies soon. There are ambitions for both IV and intramuscular/EpiPen-like delivery formats.

Therapeutic areas: Hematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

CP-101

Preclinical

Partnerships

University of Leeds (spin-out origin)o2h Ventures SEIS investment/funding partner

Beyond the preview

Go deeper on ClotProtect Therapeutics Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ClotProtect Therapeutics Limited.

Explore the full profile